Consensus AlloVir, Inc.

Equities

ALVR

US0198181036

Real-time Estimate Cboe BZX Other stock markets 03:05:13 2024-04-16 pm EDT			5-day change	1st Jan Change
0.727 ^USD	-2.56%		-1.87%	+7.38%

Mar. 20	North American Morning Briefing : Markets on Hold -2-	DJ
Mar. 15	AlloVir, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Evolution of the average Target Price on AlloVir, Inc.

Price target over the last 5 years

History of analyst recommendation changes

1fcb8f46baaa4134d132d27.1uePUwMkGSFppm5Afj5gdV57f7HRAZcVRFxT0hkErvY.p4vrNTQTUWcHlzo1TGw4AhU4G_KaddM4MQYFml9N_sewqNAlMlFWYAL-HQ~aa846be7ed703085944c369efe9932bb

Analyst Recommendations on AlloVir, Inc.

North American Morning Briefing : S&P 500 Hovers Near Record as Interest Rate Optimism Holds Sway	Dec. 27	DJ
Morgan Stanley Downgrades AlloVir to Equalweight From Overweight, Cuts Price Target to $1 From $20	Dec. 22	MT
Leerink Partners Downgrades AlloVir to Market Perform From Outperform, Cuts Price Target to $1 From $14	Dec. 22	MT
Piper Sandler Downgrades AlloVir to Neutral From Overweight, Cuts Price Target to $1.50 From $27	Dec. 22	MT
JPMorgan Downgrades AlloVir to Underweight From Overweight	Dec. 22	MT
AlloVir Shares Rise After BofA Securities Cites 'Compelling Story,' Initiates Coverage With a Buy	23-08-18	MT
BofA Securities Starts AlloVir at Buy	23-08-18	MT
SVB Securities Adjusts Price Target on AlloVir to $19 From $16, Maintains Outperform Rating	23-04-26	MT
SVB Securities Adjusts Price Target on AlloVir to $19 From $25, Maintains Outperform Rating	23-01-23	MT
SVB Securities Adjusts Price Target on AlloVir to $25 From $24, Maintains Outperform Rating	22-11-07	MT
Morgan Stanley Cuts Price Target on AlloVir to $27 From $32, Maintains Overweight Rating	22-09-09	MT
Piper Sandler Adjusts AlloVir's Price Target to $30 From $34, Reiterates Overweight Rating	22-08-05	MT
SVB Securities Adjusts AlloVir's Price Target to $23 from $30, Keeps Outperform Rating	22-07-28	MT
Piper Sandler Adjusts AlloVir's Price Target to $34 From $55, Reiterates Overweight Rating	22-05-19	MT
SVB Leerink Adjusts AlloVir Price Target to $30 From $32, Maintains Outperform Rating	22-02-10	MT
BMO Capital Starts AlloVir at Outperform with $130 Price Target	22-02-01	MT
Morgan Stanley Adjusts AlloVir Price Target to $32 From $45, Maintains Overweight Rating	22-02-01	MT
Morgan Stanley Adjusts AlloVir's Price Target to $45 from $48, Keeps Overweight Rating	22-01-18	MT
SVB Leerink Adjusts AlloVir's Price Target to $32 from $37, Keeps Outperform Rating	21-12-17	MT
SVB Leerink Adjusts Price Target on AlloVir to $37 from $41, Keeps Outperform Rating	21-11-08	MT
ALLOVIR : Morgan Stanley Adjusts Price Target on AlloVir to $48 From $47, Maintains Overweight Rating	21-10-12	MT
ALLOVIR : Morgan Stanley Adjusts Price Target on AlloVir to $47 From $50, Maintains Overweight Rating	21-08-18	MT
ALLOVIR : SVB Leerink Adjusts AlloVir PT to $42 From $41, Maintains Outperform Rating	21-05-06	MT
ALLOVIR : Morgan Stanley Adjusts Price Target on AlloVir to $50 From $49, Maintains Overweight Rating	21-04-19	MT